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Abstract
Background—In patients with symptomatic peripheral artery disease (PAD) with a history of 
limb revascularization, the optimal antithrombotic regimen for long-term management is 
unknown.  
Methods—The Examining Use of tiCagreLor In paD (EUCLID) trial randomized 13,885 
patients with PAD to treatment with ticagrelor 90mg twice daily or clopidogrel 75mg daily.
Patients were enrolled based on an abnormal ankle-brachial index (ABI) 0.80 or a prior lower 
extremity revascularization. This analysis focuses on the 7875 (57%) patients enrolled based on 
the prior lower extremity revascularization criterion. Patients could not be enrolled within 30
days of most recent revascularization, and patients with an indication for dual antiplatelet therapy 
were excluded. The primary efficacy endpoint was a composite of cardiovascular death, 
myocardial infarction, or ischemic stroke. The primary safety endpoint was major bleeding.   
Results—Patients with a prior revascularization had a mean age of 66 years, 73% were male, and 
the median baseline ABI was 0.78. After adjustment for baseline characteristics, patients 
enrolled based on prior revascularization had similar rates of the primary composite endpoint 
(hazard ratio (HR) 1.10, 95% CI 0.98-1.23, p=0.12) and statistically significantly higher rates of 
myocardial infarction (HR 1.29, 95% CI 1.08-1.55, p=0.005) and acute limb ischemia (HR 4.23, 
95% CI 2.86-6.25, p<0.001) when compared with patients enrolled based on ABI criteria. There 
were no differences in ticagrelor- versus clopidogrel-treated patients for the primary efficacy 
endpoint (11.4% vs. 11.3%; HR 1.01, 95% CI 0.88–1.15; p=0.90), all-cause mortality (9.2% vs. 
9.2%; HR 0.99, 95% CI 0.86–1.15; p=0.93), acute limb ischemia (2.5% vs. 2.5%; HR 1.03, 95% 
CI 0.78–1.36; p=0.84), or major bleeding (1.9% vs. 1.8%; HR 1.15, 95% CI 0.83–1.59; p=0.41).
The median duration of follow up was approximately 30 months. 
Conclusions—After adjustment for baseline characteristics, patients enrolled based on prior 
revascularization for PAD had higher rates of myocardial infarction and acute limb ischemia 
with similar composite rates of cardiovascular death, myocardial infarction, and stroke when
compared with patients enrolled based on the ABI criterion. There were no significant 
differences between ticagrelor and clopidogrel for reduction of cardiovascular or acute limb 
events.
Clinical Trial Registration—ClinicalTrials.gov (NCT01732822) 
Key words: lower extremity revascularization; peripheral artery disease; ticagrelor
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Clinical Perspective
What is new? 
x Patients with prior lower extremity revascularization had a heightened unadjusted risk of 
both cardiovascular and acute limb events when compared with patients who entered the 
study based on the ABI criterion.
x After adjustment for baseline characteristics, the risk of myocardial infarction and acute 
limb events remained statistically significantly higher while the risks of major adverse 
cardiovascular events and major bleeding were not statistically different in patients 
enrolled based on prior revascularization when compared with patients enrolled based on 
ABI criteria.
What are the clinical implications?
x Myocardial infarction and acute limb events were more common in patients enrolled 
based on prior revascularization when compared with patients enrolled based on ABI 
criteria.
x Ticagrelor did not reduce the primary composite endpoint of cardiovascular mortality, 
myocardial infarction, or ischemic stroke when compared with clopidogrel in patients 
with PAD and a history of lower extremity revascularization.
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Peripheral artery disease (PAD) is considered a systemic manifestation of atherosclerosis that 
affects the arteries of the lower extremities, and is often thought to constitute a coronary heart 
disease risk equivalent due to the associated high cardiovascular morbidity and mortality.1-4
Symptomatic patients most commonly present with either intermittent claudication or critical 
limb ischemia, and these are often the focus of treatment strategies to revascularize the limb.5
Unlike patients with coronary artery disease (CAD), there is limited understanding of how to 
reduce the cardiovascular risk of patients with symptomatic PAD (whether treated with 
revascularization or medical therapy), and clinicians often rely on data from subgroup analyses 
of patients with PAD in antiplatelet and statin studies to guide cardiovascular risk reduction 
strategies.6,7  
With limited proven medical therapies to reduce symptoms in patients with PAD, the use 
of peripheral endovascular and surgical revascularization for the symptomatic management of 
patients with PAD has increased dramatically over the past two decades.8,9 When compared with
revascularization for CAD, little evidence exists to guide clinicians on the choice and use of 
antiplatelet medications in patients with a history of peripheral revascularization procedures.10
The optimal antithrombotic regimen for long-term management of patients with PAD after 
revascularization is poorly defined and often extrapolated from trials of patients undergoing 
percutaneous coronary intervention.  
Two critical questions exist about the long-term prognosis and management of patients 
who have undergone prior lower extremity revascularization. First, are patients with prior 
revascularization at heightened risk for cardiovascular and limb events when compared with 
patients who have not undergone prior revascularization? Second, are more intensive antiplatelet 
medications more effective yet safe in this population? Ticagrelor is a potent P2Y12 receptor 
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antagonist with evidence of benefit in patients with acute coronary syndromes and those with 
prior myocardial infarction.11,12 The Examining Use of tiCagreLor In paD (EUCLID) trial was 
designed to evaluate treatment specifically in patients with PAD and tested the hypothesis that 
monotherapy with ticagrelor would be superior to clopidogrel in preventing cardiovascular 
endpoints in patients with PAD. This report describes the findings in the subgroup of patients 
who were enrolled based on a history of a prior lower extremity revascularization.   
Methods
Study Design and Oversight
The design of EUCLID has been previously published.13 Briefly, this was a double-blind, event-
driven clinical trial that randomized 13,885 patients with PAD from 811 study sites in 28 
countries. The trial was designed by an independent executive committee including members 
from the Duke Clinical Research Institute (DCRI; Durham, NC), Colorado Prevention Center at 
the University of Colorado School of Medicine (Aurora, CO), and AstraZeneca AB (Södertälje, 
Sweden), the trial sponsor. An international steering committee was also responsible for 
oversight of local study sites and included national lead investigators from each country. The 
DCRI managed the clinical database and conducted all analyses for publication independent of 
the sponsor. All primary efficacy and safety endpoints were adjudicated by an independent 
clinical events classification group who were blinded to treatment assignment. An independent 
data monitoring committee provided safety oversight.
Study Population
Eligible patients were \HDUVRIDJHwith lower extremity PAD. These patients were enrolled 
with an abnormal ankle-brachial index (ABI) 0.80 at screening or a prior revascularization of 
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the lower extremity >30 days prior to randomization. The primary focus of this analysis is 
patients entering the study based on the prior revascularization criterion. Key exclusion criteria 
included planned use of dual antiplatelet therapy or the use of aspirin, a high risk of bleeding, or 
treatment with anticoagulation. All patients underwent genotype testing for CYP2C19, and those 
patients with a genotype with 2 loss-of-function alleles were excluded from the study. Planned 
need for revascularization (any territory) or major amputation within 3 months was also an 
exclusion criterion. All patients provided written informed consent and institutional review 
boards approved the protocols at participating institutions.   
Data Collection 
At baseline, sites collected and recorded general demographics and clinical characteristics and 
PAD-specific characteristics from patients in the electronic case report form (eCRF). Data
regarding PAD symptom status were recorded and then categorized using the Rutherford and 
Fontaine classification systems. Additionally, investigators entered the date of and details
regarding the most recent endovascular procedure (e.g., location of intervention) and surgical 
revascularization procedure (e.g., type of operation) in the eCRF. Finally, the level of prior 
amputation was recorded for all applicable patients.
Randomization and Study Treatment
Patients were randomized 1:1 to either ticagrelor 90 mg twice daily or clopidogrel 75 mg daily 
given in a double-blind fashion. At the time of randomization, patients were required to stop the 
use of open label aspirin and/or P2Y12 inhibitors. Recruitment began in December 2012 and was 
completed in March 2014.   
Endpoints
The primary efficacy endpoint was time from randomization to first occurrence of any event in 
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the composite of cardiovascular death, myocardial infarction, or ischemic stroke. Secondary 
endpoints included the primary composite endpoint plus acute limb ischemia, cardiovascular 
death alone, myocardial infarction, all-cause mortality, the primary composite endpoint including 
all-cause stroke, acute limb ischemia alone, time to lower extremity revascularization, and time 
to any revascularization. The primary safety endpoint was Thrombolysis in Myocardial 
Infarction (TIMI) major bleeding. The components of the primary efficacy endpoint, the primary 
safety endpoint, and all hospitalizations for acute limb ischemia were adjudicated by the 
independent clinical events classification group.  
Hospitalization for acute limb ischemia was not considered a standard endpoint at the 
time of protocol development. However, the protocol was amended in December 2013 to collect 
source data for all hospitalizations for PAD, peripheral revascularization, and amputation. 
Trained adjudicators then reviewed all information to determine whether patients had acute limb 
ischemia defined as a hospitalization involving a rapid or sudden decrease in limb perfusion 
AND either (A) a new pulse deficit, rest pain, pallor, paresthesia, paralysis; OR (B) confirmation 
of arterial obstruction by limb hemodynamics (ankle or toe pressure) imaging, intra-operative 
findings, or pathological evaluation.
Statistical Analysis
The primary and secondary efficacy endpoints were analyzed using the intention-to-treat 
approach and were performed on the full analysis set consisting of all patients randomized to 
study drug irrespective of study drug adherence or withdrawal of consent. Patients who withdrew 
consent to participate in the study were included up to the date of their study termination with the 
exception of an analysis of all-cause mortality that used information from all patients for whom 
vital status could be determined via publically available records. The safety analyses were 
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performed on all patients who received at least 1 dose of study drug while on treatment, defined 
as within 7 days of the last dose of study drug. 
 The primary and secondary endpoints were analyzed in time-to-event analyses in a Cox 
proportional hazards model with a factor for treatment group. P-values and confidence intervals 
(CI) for the hazard ratios (HR) were based on the Wald statistic. Kaplan-Meier estimates of the 
cumulative proportion of patients with events were calculated and plotted.  
 Comparisons of event rates between patients enrolled based on ABI versus prior 
revascularization criteria were not pre-specified and were performed post hoc. P-values for 
differences between baseline characteristics (Table 1 and 2) were calculated using Chi-square 
FHOOVL]HDQG)LVKHU¶VH[DFWWHVWFHOOVL]HIRUFDWHJRULFDOYDULDEOHVDQG:LOFR[RQ¶VWHVW
for continuous variables. Adjusted analyses for the primary composite endpoint, components of 
the primary composite endpoint, ALI, and major bleeding (using baseline variables shown in 
Table 1) were performed to determine whether patients entering the study based on prior 
revascularization had higher rates of cardiovascular and acute limb events when compared with 
patients entering the study based on ABI criteria.
SAS version 9.4 was used for all analyses and all tests were two-sided.
Results
From December 2012 to March 2014, a total of 16,237 patients were enrolled and screened for 
randomization. After exclusion, 13,885 patients were randomized and followed for primary 
events until the primary analysis censoring date of May 9, 2016. A total of 7875 (57%) patients 
entered the study based on the prior lower extremity revascularization criterion. At the 
completion of the EUCLID study, a total of 14 patients did not have vital status known, of whom 
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5 were lost to follow up. The median length of follow up was approximately 30 months. 
Baseline characteristics
Baseline characteristics by treatment assignment for patients who entered the study with a 
history of lower extremity revascularization are presented in Table 1. Patients had a mean age of 
66 years, 73% were male, and the median baseline ABI was 0.78. When compared with patients 
enrolled on the ABI criterion, a lower proportion of patients enrolled based on prior 
revascularization were female (27.0% vs. 29.3%, p=0.004), while a higher proportion were from 
North America (28.6% vs. 13.2%, p<0.001), had carotid stenosis (19.0 vs. 15.3%, p<0.001), had 
undergone prior PCI or CABG (26.3% vs. 19.1%, p<0.001), and had vascular disease in >1 
vascular bed (46.2% vs. 40.7%, p<0.001) (Supplemental Table). Patients with prior 
revascularization were more commonly current or former smokers, had a higher prevalence of 
lipid disorders, and a lower prevalence of diabetes mellitus. Patients with prior revascularization 
were also more commonly treated with cardioprotective medications including aspirin, 
clopidogrel, and statins prior to participation in the study, as compared with those enrolled based 
on the ABI criterion.
PAD-Specific and Prior Revascularization Characteristics
PAD-specific and prior revascularization baseline characteristics are presented in Table 2. At the 
time of enrolment, limb symptoms in patients with prior revascularization included intermittent 
claudication (64.0%) and critical limb ischemia (4.5%); 31.4% of patients were asymptomatic. In 
terms of most recent revascularization procedure prior to randomization, 63.5% of patients had 
endovascular revascularization and 36.3% had surgical revascularization. Notably, in 31.1% of 
patients the most recent revascularization procedure occurred between 30 days and 6 months 
prior to randomization, 31.4% between 6 months and 2 years prior to randomization, and 36.7%
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>2 years prior to randomization. Additionally, 7.5% of patients with prior revascularization had 
previously undergone prior amputation (1.7% above knee amputation; 1.1% below knee 
amputation; 4.6% minor amputation including ankle disarticulation, foot and toe amputation) 
(Supplemental Table 1).
Event Rates in Prior Revascularization vs. ABI Groups 
When compared with patients enrolled based on the ABI criterion, patients enrolled based on 
prior revascularization had higher rates of the primary composite endpoint (11.4% vs. 9.9%; HR 
1.13, 95% CI 1.02–1.26; p=0.02), myocardial infarction (5.9% vs. 3.6%; HR 1.63 95% CI 1.38-
1.91 p<0.001), acute limb ischemia (2.5% vs. 0.6%; HR 4.13, 95% CI 2.90–5.90; p<0.001), and 
TIMI major bleeding (1.8% vs. 1.3%; HR 1.41, 95% CI 1.07–1.85; p=0.01) (Table 3). 
After adjustment for baseline variables, patients enrolled based on prior revascularization 
had non-statistically significantly higher rates of the primary composite endpoint (HR 1.10, 95% 
CI 0.98-1.23, p=0.12) but statistically significantly higher rates of MI (HR 1.29, 95% CI 1.08-
1.55, p=0.005) and ALI (HR 4.23, 95% CI 2.86-6.25, p<0.001) when compared with patients 
enrolled based on ABI criteria (Table 3).   
Efficacy Endpoint Based on Treatment Comparisons
In patients with a history of revascularization, the primary efficacy endpoint of cardiovascular 
death, myocardial infarction, or ischemic stroke occurred in 11.4% of ticagrelor- versus 11.3% of 
clopidogrel-treated patients (HR 1.01, 95% CI 0.88–1.15; p=0.90) (Figure 1). The annualized 
event rate for acute limb ischemia was 1.01% in the ticagrelor group and 0.99% in the 
clopidogrel group. Other key secondary and composite endpoints including repeat 
revascularization were not different between treatment groups (Table 4).   
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Safety Endpoints Based on Treatment Comparisons
In patients with a history of revascularization, the primary safety endpoint, TIMI major bleeding,
occurred in 1.9% of ticagrelor- versus 1.8% of clopidogrel-treated patients (HR 1.15, 95% CI 
0.83–1.59; p=0.41) (Figure 2). Fatal bleeding, intracranial bleeding, and TIMI minor bleeding 
were all low frequency events and not different between treatment groups (Table 5).
There was no heterogeneity of treatment effects observed in those patients enrolled with 
versus without a history of limb revascularization (primary composite efficacy endpoint, 
pinteraction=0.72; primary safety endpoint, pinteraction=0.67). Additionally, when an on treatment 
analysis was performed in patients enrolled based on prior lower extremity revascularization, 
there were no significant differences in rates of the primary composite endpoint, components of 
the primary composite endpoint, or ALI between ticagrelor- and clopidogrel-treated patients.
Discussion
A primary finding of this subgroup was that the adjusted rates of MI and ALI were higher in 
patients enrolled based on prior lower extremity revascularization when compared with patients 
enrolled based on ABI criteria. Additionally, ticagrelor did not reduce the rate of major 
cardiovascular or acute limb endpoints when compared with clopidogrel in the overall population 
of patients with PAD in the EUCLID trial.[manuscript in press] This was also true in patients 
with PAD who entered the study based on the prior revascularization criterion. These findings 
suggest that patients with prior revascularization have a substantial residual rate of 
cardiovascular and acute limb events, despite high adherence to antiplatelet and statin 
medications, and require further study. 
This study of patients with a history of limb revascularization is a representative cohort of 
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patients treated in contemporary clinical practice; 63.5% of patients had most recently undergone 
endovascular revascularization while 36.3% of patients had most recently undergone surgical 
revascularization. Because these patients met entry criteria based on the prior revascularization 
criterion, they were not required to be symptomatic (although 68.6% of patients reported 
symptoms at the time of enrollment). Notably, women were less likely to be enrolled based on 
prior lower extremity revascularization when compared with patients enrolled based on ABI 
criteria. Approximately one-third of patients who had undergone endovascular revascularization 
were most recently treated for disease of the iliac arteries and another one-third were treated for 
disease of the superficial femoral arteries, while the remaining patients had revascularization for 
disease of the common femoral, popliteal, and tibial arteries. Among patients with a history of 
limb revascularization, the most common surgical revascularization procedures prior to entering 
the trial were common or superficial femoral endarterectomy (6.0%), aorto-bifemoral bypass 
(5.7%), femoropopliteal (above knee) bypass (7.7%), and femoropopliteal (below knee) bypass 
(4.8%).
 The current findings suggest that patients with a history of peripheral revascularization 
represent a cohort with a heightened risk of MI and ALI when compared with patients enrolled 
based on ABI criteria despite higher use of antiplatelet and statin drugs on entry. While the 
difference in risk of the primary composite endpoint was no longer statistically significant after 
adjustment for baseline factors, the critical question remaining is whether the medical 
community can determine treatment strategies to reduce risk and event rates in this population. 
To this point, there are few consensus statements available to guide clinicians in treating patients 
with PAD. Most of the empiric evidence has been derived from patients with stable PAD (i.e.,
not at the time of revascularization), including the CAPRIE subgroup analysis demonstrating a
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reduction in cardiovascular events in patients with PAD taking clopidogrel as compared with 
aspirin.6 Expert opinion regarding optimal antithrombotic medication use after revascularization 
has been extrapolated from literature developed in patients undergoing coronary 
revascularization procedures. The majority of the literature in PAD after endovascular 
revascularization was derived from studies of patients undergoing angioplasty alone and without 
sufficient information regarding disease burden and severity. Indeed, patients are currently being 
treated with advanced techniques including hybrid revascularization, trans-pedal access, and/or 
newer devices (e.g., atherectomy, drug-eluting stents, drug-coated balloons). It is clear that 
current invasive treatment approaches have outstretched the knowledge base for use of 
antiplatelet and concomitant medical therapies following revascularization.
While the EUCLID trial was not designed to specifically evaluate the use of ticagrelor 
after revascularization and there were no patients in EUCLID who were randomized while on 
dual antiplatelet therapy, this represents a large study of antiplatelet therapies in patients with 
PAD enrolled after revascularization procedures. As such, this subgroup analysis of the EUCLID 
trial has specifically focused on the long-term prevention of cardiovascular and acute limb events
in this high-risk cohort of patients with a history of lower extremity revascularization. The 
results suggest that in patients with a history of revascularization (>30 days prior to enrollment) 
and for whom dual antiplatelet therapy was not required, antiplatelet inhibition with ticagrelor 
compared with clopidogrel does not provide additional benefit to reduce long-term 
cardiovascular and acute limb events.
The present findings not only add context to the current knowledge of antiplatelet 
monotherapy after revascularization for PAD, but they also highlight the need for more trials of 
antithrombotic agents after revascularization. Specifically, there is a lack of evidence about 
 by guest on November 26, 2016
http://circ.ahajournals.org/
Downloaded from 
10.1161/CIRCULATIONAHA.116.025880
14
whether patients should be treated with 1 or 2 antiplatelet agents, which agents should be used, 
duration of antiplatelet monotherapy or dual therapy, and whether antithrombotics that utilize 
different mechanistic pathways (e.g., P2Y12 receptor antagonists, factor Xa inhibitors) should be 
used in isolation or in combination for these complex patients to reduce the long-term rates of 
cardiovascular events and acute limb ischemia. Finally, it is imperative to understand the impact 
of disease presentation, anatomic burden of disease, and type of revascularization procedures as 
the optimal antiplatelet medication regimen is being studied and developed.
There are limitations in this subgroup of patients with PAD who have undergone prior 
revascularization. First, all patients had to be >30 days from most recent revascularization 
procedure; thus no patients were enrolled immediately after revascularization. While an 
important evidence gap, 31.1% of patients were enrolled within 6 months of most recent 
revascularization, which constitutes an important potentially higher risk period for these patients 
with PAD. Second, despite the fact that this is a pre-specified subgroup analysis of the larger 
EUCLID trial, it is by far the largest cohort of patients with PAD and a history of 
revascularization enrolled to date in a clinical trial of antiplatelet medications. It is also important 
to note that patients deemed likely to require a new revascularization or amputation within 3 
months were excluded from enrollment; thus the study population reflects clinically significant 
but stable PAD. 
In conclusion, ticagrelor did not reduce the primary composite endpoint of cardiovascular 
mortality, myocardial infarction, or ischemic stroke when compared with clopidogrel in patients 
with PAD and a history of revascularization. After adjustment for baseline variables, the risk of 
MI and ALI remained statistically significantly higher while the risks of the primary composite 
endpoint and major bleeding were similar in patients enrolled based on prior revascularization 
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when compared with patients enrolled based on ABI criteria. While the EUCLID trial was not 
designed to singularly study the optimal antiplatelet medication regimen after lower extremity 
revascularization, the current findings highlight the need for future studies to better guide 
clinicians in treating patients post revascularization.
Acknowledgments: We thank Elizabeth Cook from the Duke Clinical Research Institute, who 
provided editorial assistance with the preparation the manuscript.
Funding Source: The EUCLID trial was supported by AstraZeneca. 
Conflict of Interest Disclosures:
Jones: Institutional research grant from AstraZeneca.  
Baumgartner: Research grants from Abbott Vascular, Cook, Optimed, Terumo, Promedics, 
Amgen, and Boston Scientific; Consulting fees from Astra Zeneca, Bayer, and Sanofi. 
Hiatt: Institutional research grants from AstraZeneca, Bayer, Pleuristem, National Institutes of 
Health, and Kuyshu University Japan. 
Heizer, Reist, White: Nothing to disclose  
Conte: Consulting fees from Medtronic and Cook. 
Berger: Institutional research grants from Astra Zeneca, National Heart, Lung, and Blood 
Institute, and American Heart Association; Consulting fees from Janssen, Merck, and Takeda.
Held, Katona, Blomster, Millegård: Employed by AstraZeneca
Mahaffey: Institutional research grants from Amgen, Daiichi, Johnson & Johnson, Medtronic, 
Merck, St. Jude, and Tenax; Consulting fees from AstraZeneca, American College of 
Cardiology, BAROnova, Bayer, Bio2 Medical, Boehringer Ingelheim, Bristol-Myers Squibb, 
Cubist, Eli Lilly, Elsevier, Epson, Forest, GlaxoSmithKline, Johnson & Johnson, Medtronic, 
Merck, Mt. Sinai, Myokardia, Omthera, Portola, Purdue Pharma, Springer Publishing, The 
Medicines Company, Theravance, Vindico, and WebMD; Equity in BioPrint Fitness.  
Norgren: Research grants from AnGes and Mitsubishi; Consulting fees from AstraZeneca, 
Bayer, AnGes, Pluristem, CESCA, and Mitsubishi.  
Patel: Institutional research grants from AstraZeneca, CSL, HeartFlow, Janssen Research & 
 by guest on November 26, 2016
http://circ.ahajournals.org/
Downloaded from 
10.1161/CIRCULATIONAHA.116.025880
16
Development, Johnson & Johnson, Maquet, Medtronic, and National Heart, Lung, and Blood 
Institute; Consulting fees from Bayer Corporation, CSL, Genzyme, Janssen Research & 
Development, Medtronic, and Merck & Co.  
Fowkes: Consulting fees from AstraZeneca, Bayer, and Merck.  
References
1. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With 
Peripheral Artery Disease (Updating the 2005 Guideline): A Report of the American 
College of Cardiology Foundation/American Heart Association Task Force on Practice 
Guidelines. Circulation. 2011;124:2020-2045. 
2. European Stroke Organisation, Tendera M, Aboyans V, Bartelink ML, Baumgartner I, 
Clément D, Collet JP, Cremonesi A, De Carlo M, Erbel R, Fowkes FG, Heras M, 
Kownator S, Minar E, Ostergren J, Poldermans D, Riambau V, Roffi M, Röther J, Sievert 
H, van Sambeek M, Zeller T; ESC Committee for Practice Guidelines. ESC Guidelines 
on the diagnosis and treatment of peripheral artery diseases: Document covering 
atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and 
lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral 
Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J.
2011;32:2851-2906. 
3. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG; TASC II 
Working Group. Inter-Society Consensus for the Management of Peripheral Arterial 
Disease (TASC II). J Vasc Surg. 2007;45SupplS:S5-67. 
4. Society for Vascular Surgery Lower Extremity Guidelines Writing Group., Conte MS, 
Pomposelli FB, Clair DG, Geraghty PJ, McKinsey JF, Mills JL, Moneta GL, Murad MH, 
Powell RJ, Reed AB, Schanzer A, Sidawy AN. Society for Vascular Surgery practice 
guidelines for atherosclerotic occlusive disease of the lower extremities: management of
asymptomatic disease and claudication. J Vasc Surg. 2015;61(3 Suppl):2S-41S. 
5. McDermott MM, Greenland P, Liu K, Guralnik JM, Criqui MH, Dolan NC, Chan C, 
Celic L, Pearce WH, Schneider JR, Sharma L, Clark E, Gibson D, Martin GJ. Leg 
symptoms in peripheral arterial disease: associated clinical characteristics and functional 
impairment. JAMA. 2001;286:1599-1606. 
6. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin 
in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339. 
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of 
cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised 
placebo-controlled trial. Lancet. 2002;360:7-22. 
8. Jones WS, Mi X, Qualls LG, Vemulapalli S, Peterson ED, Patel MR, Curtis LH. Trends 
in settings for peripheral vascular intervention and the effect of changes in the outpatient 
prospective payment system. J Am Coll Cardiol. 2015;65:920-927. 
9. Goodney PP, Beck AW, Nagle J, Welch HG, Zwolak RM. National trends in lower 
extremity bypass surgery, endovascular interventions, and major amputations. J Vasc 
Surg. 2009;50:54-60. 
 by guest on November 26, 2016
http://circ.ahajournals.org/
Downloaded from 
10.1161/CIRCULATIONAHA.116.025880
17
10. Berger JS, Hiatt WR. Medical therapy in peripheral artery disease. Circulation. 
2012;126:491-500. 
11. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, 
Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, 
Harrington RA; PLATO Investigators. Ticagrelor versus clopidogrel in patients with 
acute coronary syndromes. N Engl J Med. 2009;361:1045-1057. 
12. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal 
S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm 
C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald 
E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators.. Long-term 
use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 
2015;372:1791-1800. 
13. Berger JS, Katona BG, Jones WS, Patel MR, Norgren L, Baumgartner I, Blomster J, 
Mahaffey KW, Held P, Millegård M, Heizer G, Reist C, Fowkes FG, Hiatt WR. Design 
and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral 
Artery Disease (EUCLID) trial. Am Heart J. 2016;175:86-93. 
 by guest on November 26, 2016
http://circ.ahajournals.org/
Downloaded from 
10.1161/CIRCULATIONAHA.116.025880
18
Table 1. Baseline characteristics of patients with prior revascularization according to treatment 
group 
Ticagrelor
(n=3923)
Clopidogrel
(n=3952)
p value
Age, median (25th, 75th), yrs 66.0 (60.0, 72.0) 66.0 (60.0, 72.0) 0.25
Female sex, no. (%) 1041 (26.5) 1088 (27.5) 0.32
Weight, median (25th, 75th), kg 76.0 (65.2, 88.0) 76.0 (65.6, 88.0) 0.58
Region, no. (%) 0.80
North America 1111 (28.3) 1139 (28.8)
Europe 1921 (49.0) 1951 (49.4)
Asia 593 (15.1) 569 (14.4)
Central/South America 298 (7.6) 293 (7.4)
Medical history, no. (%)
History of stroke 338 (8.6) 325 (8.2) 0.53
History of TIA 164 (4.2) 145 (3.7) 0.24
History of carotid stenosis 751 (19.1) 748 (18.9) 0.80
Prior carotid revascularization 126 (3.2) 108 (2.7) 0.21
History of coronary artery 
disease**
1211 (30.9) 1233 (31.2) 0.76
Prior MI 673 (17.2) 715 (18.1) 0.28
Prior PCI or CABG 1046 (26.7) 1024 (25.9) 0.44
Number of vascular beds* 0.65
1 2119 (54.0) 2119 (53.6)
2 1345 (34.3) 1389 (35.1)
3 459 (11.7) 444 (11.2)
Diabetes mellitus 1410 (35.9) 1424 (36.0) 0.94
Hypertension 3070 (78.3) 3102 (78.5) 0.82
Hyperlipidemia 3081 (78.5) 3125 (79.1) 0.57
Tobacco use, no. (%) 0.59
Never smoked 620 (15.8) 598 (15.1)
Current smoker 1251 (31.9) 1296 (32.8)
Former smoker 2017 (51.4) 2035 (51.5)
Medications at baseline, no. (%)
Aspirin 2885 (73.5) 2879 (72.8) 0.49
Clopidogrel 1571 (40.8) 1652 (41.8) 0.11
Statins 3007 (76.7) 3090 (78.2) 0.10
ACE inhibitor 1599 (40.8) 1573 (39.8) 0.39
Angiotensin receptor blocker 921 (23.5) 979 (24.8) 0.18
Cilostazol 588 (15.0) 589 (14.9) 0.92
*A vascular bed is defined as either PAD, prior CAD (prior MI, prior PCI, or prior CABG), or prior cerebrovascular 
disease (prior stroke, prior TIA, prior carotid artery stenosis or prior carotid revascularization).
**CAD is defined as if the patient either had a prior MI, prior PCI or prior CABG.
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Table 2. PAD-specific baseline characteristics of patients with prior revascularization according 
to treatment group. 
Ticagrelor
(N=3923)
Clopidogrel
(N=3952)
p value
ABI values at baseline, median (25th, 75th)* 0.78 (0.62, 0.94) 0.78 (0.61, 0.94) 0.89
Type of most recent prior revascularization, no. (%) 0.42
Surgical 1443 (36.8) 1419 (35.9)
Endovascular 2475 (63.1) 2528 (64.0)
Time since most recent lower extremity revascularization 0.49
>30 days - 6 months 1197 (30.5) 1256 (31.8)
>6 months - 2 years 1243 (31.7) 1226 (31.0)
>2 years 1450 (37.0) 1442 (36.5)
Location of prior endovascular revascularization, no. (%) N/A
Iliac 1315 (33.5) 1359 (34.4)
Common femoral artery 325 (8.3) 304 (7.7)
Superficial femoral artery 1328 (33.9) 1351 (34.2)
Popliteal 464 (11.8) 476 (12.0)
Tibial 252 (6.4) 287 (7.3)
Type of prior surgical revascularization, no. (%) N/A
Endarterectomy (CFA/SFA) 387 (9.9) 407 (10.3)
Aorto-bifemoral bypass 397 (10.1) 383 (9.7)
Axillary bifemoral bypass 40 (1.0) 45 (1.1)
Femoropopliteal bypass (above knee) 515 (13.1) 499 (12.6)
Femoropopliteal bypass (below knee) 314 (8.0) 355 (9.0)
Other 360 (9.2) 349 (8.8)
Limb symptoms upon study entry, no. (%)† 0.80
Asymptomatic‡ 1253 (31.9) 1223 (30.9)
Mild/moderate claudication 1799 (45.9) 1850 (46.8)
Severe claudication 695 (17.7) 702 (17.8)
Rest pain 95 (2.4) 109 (2.8)
Minor tissue loss (ischemic ulceration not exceeding 
ulcer of the digits of the foot)
60 (1.5) 57 (1.4)
Major tissue loss (severe ischemic ulcers or frank 
gangrene)
20 (0.5) 10 (0.3)
Prior amputation, no. (%) 300 (7.6) 291 (7.4) 0.07
Above knee amputation 58 (1.5) 79 (2.0)
Below knee amputation 242 (6.2) 215 (5.4)
Transtibial amputation 51 (1.3) 37 (0.9)
Ankle disarticulation 4 (0.1) 3 (0.1)
Partial foot amputation 26 (0.7) 25 (0.6)
Toe amputation 161 (4.1) 147 (3.7)
*ABI is calculated from site-reported measurements in the CRF, and is calculated as the average of enrollment and 
randomization ABI (or TBI) measurements, where at each visit, the lowest of the right and left ABIs (or TBIs) is 
selected.
†Using the Rutherford classification.
‡Symptom status at time of randomization (patients with a prior revascularization may have been asymptomatic at 
baseline).
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Table 4. Efficacy endpoints for patients with prior revascularization according to treatment 
group. 
Ticagrelor
(N=3923)
Clopidogrel
(N=3952) HR (95% CI) P value
Primary outcome: Composite of CV death,
MI, or ischemic stroke
447 (11.4%) 447 (11.3%) 1.01 (0.88–1.15) 0.898
Event rate, %/100 pt-yrs 4.67 (4.26, 5.12) 4.63 (4.22, 5.08)
CV death 190 (4.8%) 182 (4.6%) 1.05 (0.86–1.29) 0.634
Event rate, %/100 pt-yrs 1.91 (1.65, 2.20) 1.81 (1.57, 2.10)
MI 237 (6.0%) 229 (5.8%) 1.05 (0.87–1.25) 0.629
Event rate, %/100 pt-yrs 2.46 (2.16, 2.79) 2.35 (2.07, 2.68)
Ischemic stroke 76 (1.9%) 100 (2.5%) 0.76 (0.57–1.03) 0.078
Event rate, %/100 pt-yrs 0.77 (0.62, 0.97) 1.01 (0.83, 1.23)
Key secondary efficacy outcome: 
Composite of CV death, MI, ischemic 
stroke, and ALI requiring hospitalization
522 (13.3%) 529 (13.4%) 1.00 (0.88–1.12) 0.947
Other secondary outcomes
All-cause mortality 359 (9.2%) 364 (9.2%) 0.99 (0.86–1.15) 0.925
Composite of CV death, MI, or all-
cause stroke
456 (11.6%) 461 (11.7%) 1.00 (0.88–1.14) 0.970
ALI 99 (2.5%) 97 (2.5%) 1.03 (0.78–1.36) 0.835
Event rate, %/100 pt-yrs 1.01 (0.83, 1.24) 0.99 (0.81, 1.20)
Lower extremity revascularization 654 (16.7%) 680 (17.2%) 0.97 (0.87–1.07) 0.519
Composite of all revascularization 
(coronary and peripheral [limb, 
mesenteric, renal, carotid, and other])
906 (23.1%) 914 (23.1%) 1.00 (0.91–1.09) 0.929
Data presented as no. (%), unless otherwise indicated.
Table 5. Safety endpoints for patients with prior revascularization according to treatment group 
(on-treatment population). 
Ticagrelor
(N=3911)
Clopidogrel
(N=3938) HR (95% CI) P value
Primary safety outcome: TIMI major bleeding 74 (1.9%) 69 (1.8%) 1.15 (0.83–1.59) 0.413
Intracranial bleeding 22 (0.6%) 22 (0.6%) 1.06 (0.59–1.92) 0.840
Fatal bleeding 5 (0.1%) 11 (0.3%) 0.49 (0.17–1.40) 0.180
TIMI minor bleeding 62 (1.6%) 51 (1.3%) 1.30 (0.89–1.88) 0.171
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Figure Legends:
Figure 1. Kaplan-Meier plot of primary efficacy outcome (composite of CV death, MI, or 
ischemic stroke). 
Figure 2. Kaplan-Meier plot of primary safety outcome (TIMI major bleeding). 
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Supplemental Material 
Supplemental Table 1. Baseline characteristics and PAD characteristics of patients 
enrolled based on prior lower extremity revascularization when compared with ABI 
criteria 
 
Enrolled Based 
on Prior 
Revascularization
(N=7875) 
Enrolled Based 
on ABI 
(N=6010) P value 
Total EUCLID 
Population 
(N=13885) 
Age, median (25th, 75th), yrs 66.0 (60.0,72.0) 66.0 (61.0,73.0) <.001 66.0 (60.0,73.0)
Female sex, no. (%) 2129 (27.0) 1759 (29.3) 0.004 3888 (28.0) 
Weight, median (25th, 75th), kg 76.0 (65.5, 88.0) 77.0 (67.0, 88.0) 0.047 76.5 (66.0, 88.0)
Region, no. (%)   <.001  
North America 2250 (28.6) 795 (13.2)  3045 (21.9) 
Europe 3872 (49.2) 3626 (60.3)  7498 (54.0) 
Asia 1162 (14.8) 440 (7.3)  1602 (11.5) 
Central/South America 591 (7.5) 1149 (19.1)  1740 (12.5) 
PAD history     
ABI values at baseline, median 
(25th, 75th)* 
0.78 (0.61, 0.94) 0.65 (0.54, 0.73) <.001 0.70 (0.58, 0.82)
Type of prior revascularization, 
no. (%) 
  0.037  
Surgical 2862 (36.3) 24 (0.4)§§  2886 (20.8) 
Endovascular 5003 (63.5) 23 (0.4)§§  5026 (36.2) 
Time since most recent lower 
extremity revascularization 
  NA  
 Enrolled Based 
on Prior 
Revascularization
(N=7875) 
Enrolled Based 
on ABI 
(N=6010) P value 
Total EUCLID 
Population 
(N=13885) 
  >30 days - ≤6 months 2453 (31.1) 3 (0.0)  2456 (17.7) 
  >6 months - ≤2 years 2469 (31.4) 15 (0.2)  2484 (17.9) 
  >2 years 2892 (36.7) 29 (0.5)  2921 (21.0) 
Type of prior surgical 
revascularization, no. (%) 
  NA 3495 (25.2) 
Endarterectomy (CFA/SFA) 794 (10.1) 17 (0.3)  811 (5.8) 
Aorto-bifemoral bypass 780 (9.9) 37 (0.6)  817 (5.9) 
Axillary bifemoral bypass 85 (1.1) 4 (0.1)  89 (0.6) 
Femoropopliteal bypass 
(above knee) 
1014 (12.9) 22 (0.4)  1036 (7.5) 
Femoropopliteal bypass (below 
knee) 
669 (8.5) 36 (0.6)  705 (5.1) 
Other 709 (9.0) 35 (0.6)  744 (5.4) 
Limb symptoms upon study entry, 
no. (%)† 
  <.001  
Asymptomatic‡ 2476 (31.4) 125 (2.1)  2601 (18.7) 
Mild/moderate claudication 3649 (46.3) 3761 (62.6)  7410 (53.4) 
Severe claudication 1397 (17.7) 1831 (30.5)  3228 (23.2) 
Rest pain 204 (2.6) 174 (2.9)  378 (2.7) 
 Enrolled Based 
on Prior 
Revascularization
(N=7875) 
Enrolled Based 
on ABI 
(N=6010) P value 
Total EUCLID 
Population 
(N=13885) 
Minor tissue loss (ischemic 
ulceration not exceeding ulcer 
of the digits of the foot) 
117 (1.5) 90 (1.5)  207 (1.5) 
Major tissue loss (severe 
ischemic ulcers or frank 
gangrene) 
30 (0.4) 28 (0.5)  58 (0.4) 
Prior amputation, no. (%) 591 (7.5) 330 (5.5) <.001 921 (6.6) 
Above knee amputation 137 (1.7) 65 (1.1)  202 (1.5) 
Below knee amputation 454 (5.8) 265 (4.4)  719 (5.2) 
Transtibial amputation 88 (1.1) 49 (0.8)  137 (1.0) 
Ankle disarticulation 7 (0.1) 3 (0.0)  10 (0.1) 
Partial foot amputation 51 (0.6) 38 (0.6)  89 (0.6) 
Toe amputation 308 (3.9) 175 (2.9)  483 (3.5) 
Medical history, no. (%)     
History of stroke 663 (8.4) 480 (8.0) 0.358 1143 (8.2) 
History of TIA 309 (3.9) 198 (3.3) 0.050 507 (3.7) 
History of carotid stenosis 1499 (19.0) 922 (15.3) <.001 2421 (17.4) 
    History of coronary artery disease 2444 (31.0) 1588 (26.4) <0.001 4032 (29.0) 
Prior MI 1388 (17.6) 1134 (18.9) 0.060 2522 (18.2) 
Prior PCI or CABG 2070 (26.3) 1149 (19.1) <.001 3219 (23.2) 
 Enrolled Based 
on Prior 
Revascularization
(N=7875) 
Enrolled Based 
on ABI 
(N=6010) P value 
Total EUCLID 
Population 
(N=13885) 
Number of vascular beds§   <.001  
1 4238 (53.8) 3566 (59.3)  7804 (56.2) 
2 2734 (34.7) 1954 (32.5)  4688 (33.8) 
3 903 (11.5) 490 (8.2)  1393 (10.0) 
Diabetes mellitus 2834 (36.0) 2511 (41.8) <.001 5345 (38.5) 
Hypertension 6172 (78.4) 4685 (78.0) 0.554 10857 (78.2) 
Hyperlipidemia 6206 (78.8) 4274 (71.1) <.001 10480 (75.5) 
Tobacco use, no. (%)   <.001  
Never smoked 1218 (15.5) 1766 (29.4)  2984 (21.5) 
Current smoker 2547 (32.3) 1742 (29.0)  4289 (30.9) 
Former smoker 4052 (51.5) 2478 (41.2)  6530 (47.0) 
Medications at baseline, no. (%)     
Aspirin 5764 (73.2) 3507 (58.4) <.001 9271 (66.8) 
Clopidogrel 3223 (40.9) 1250 (20.8) <.001 4473 (32.2) 
Statins 6097 (77.4) 4084 (67.9) <.001 10181 (73.3) 
ACE inhibitor 3172 (40.3) 2463 (41.0) 0.404 5635 (40.6) 
Angiotensin receptor blocker 1900 (24.1) 1588 (26.4) 0.002 3488 (25.1) 
Cilostazol 1177 (14.9) 918 (15.3) 0.592 2095 (15.1) 
*ABI is calculated from site-reported measurements in the CRF, and is calculated as the average of 
enrollment and randomization ABI (or TBI) measurements, where at each visit, the lowest of the right and 
left ABIs (or TBIs) is selected. 
†Using the Rutherford classification. 
‡Symptom status at time of randomization (patients with a prior revascularization may have been 
asymptomatic at baseline). 
§A vascular bed is defined as either PAD, prior CAD (prior MI, prior PCI, or prior CABG), or prior 
cerebrovascular disease (prior stroke, prior TIA, prior carotid artery stenosis or prior carotid 
revascularization). 
§§ Some patients enrolled based on ABI criteria were later noted to have undergone prior 
revascularization. Since they were enrolled based on this criterion, they were analyzed as part of this 
group. 
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